Announcements Trials
Browse Landscape

Phase

Phase 3 18Phase 2 17Phase 1/2 5Phase 1 4Phase 4 2Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Lymphoid 2Plasma cell 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Carboplatin 16Pemetrexed 15Cisplatin 15Erlotinib Hydrochloride 13icotinib 8Propofol 7Gefitinib 7Gemcitabine 6Docetaxel 6endostar protein 5Saline Solution 5Paclitaxel 5Nivolumab 5Endostatins 5tislelizumab 4lorlatinib 4anlotinib 4Vinorelbine 4Sevoflurane 4Drug Therapy 4Afatinib 4pembrolizumab 3durvalumab 3atezolizumab 3Zoledronic Acid 3Radiotherapy 3Dexamethasone 3Acetaminophen 3trilaciclib 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Crizotinib × Thoracic × Clear all
NCT05160922 2026-03-30

Crizotinib Continuation Clinical Study

Pfizer

Phase 4 Active not recruiting
27 enrolled
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Pfizer

Phase 4 Terminated
41 enrolled 9 charts
Thoracic

ALK or ROS1-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡